Grant of Options

RNS Number : 1506A

Redx Pharma plc

22 December 2017

 

REDX PHARMA PLC

("Redx" or "the Company")

Grant of Options

Alderley Park, December 22 2017- Redx Pharma (AIM:REDX), the drug discovery and development company, today announces that on 21 December 2017 options over 500,000 ordinary shares of 1p each in the share capital of the Company, were granted to Dominic Jackson, Chief Financial Officer, under Redx's Enterprise Management Incentive Scheme.

One-third of the options are exercisable at a price of 22p and will vest immediately, one-third are exercisable at a price of 33p and will vest on the 1 year anniversary of the grant, and one-third are exercisable at a price of 50p and will vest on the 2 year anniversary of the grant. None of these options will become exercisable until the second anniversary of grant.

In addition, options over 3,260,000 ordinary shares of 1p each in the share capital of the Company were granted to the management and staff of the Company, also under Redx's Enterprise Management Incentive Scheme.  These options are exercisable at the same prices and on the same terms as above.

For further information, please contact:

Redx Pharma Plc	T: [phone]
Iain Ross, Executive Chairman
Cantor Fitzgerald Europe (Nominated Advisor & Broker)	T: [phone]
Phil Davies
WG Partners LLP (Joint Broker)	T: [phone]
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting	T: [phone]
Simon Conway/Stephanie Cuthbert

About Redx Pharma

Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, Redx pursues targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, the Company is focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas Redx's aim is to develop drugs whose profile suggests they will be best in class, if not first in class.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Dominic Jackson
2	Reason for notification
a.	Position/Status	Chief Financial Officer
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Redx Pharma Plc
b.	LEI	213800HMS4EBXO589Y37
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over Ordinary Shares of 1p each ISIN: GB00BSNB6S51
b.	Nature of the transaction	Grant of options under the EMI Share Scheme
c.	Price(s) and volume(s)	Option awarded over 166,667 shares at an exercise price of 22p per share Option awarded over 166,667 shares at an exercise price of 33p per share Option awarded over 166,666 shares at an exercise price of 50p per share
d.	Aggregated information - Aggregated Volume - Price	N/A - Single Transaction
e.	Date of the transaction	21/12/17
f.	Place of the transaction	Outside of trading venue

 

END

 

 

DSHUAVRRBNAUUUA